Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
How do you approach significant change in BMD in premenopausal patient on tamoxifen?
Related Questions
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy?
In a patient with a history of parathyroidectomy (due to primary hyperparathyroidism) with low T- scores and high risk of fractures, is there any contraindication to give teriparatide/Forteo if PTH is in normal range after surgery?
When interpreting bone density reports, are T-scores adjusted for different age brackets?
Do you use bone turnover markers to assess medical adherence in patients treated for osteoporosis?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
Is Evenity appropriate for a patient with severe osteoporosis (T-score -3.1) unresponsive to bisphosphonates and persistent primary hyperparathyroidism despite two surgeries?
Is there a maximum duration for raloxifene use?
Would you start romosozumab in an active smoker?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
